ZARVY

Aquazide 25 is a diuretic medication containing Hydrochlorothiazide 25mg, manufactured by Sun Pharmaceuticals. It is widely prescribed to manage high blood pressure, reduce fluid retention (edema), and support cardiovascular and renal function. As a generic version of Esidrix, it offers reliable therapeutic effects with improved accessibility.

Hydrazide 25 contains Hydrochlorothiazide 25mg, a thiazide-type diuretic commonly used to treat high blood pressure and fluid retention (edema). Manufactured by Micro Labs, this medication is a cost-effective generic alternative to Esidrix, helping to reduce blood volume and control swelling. Its dual effect on cardiovascular health and fluid balance also makes it useful as a supportive aid in weight management and dietary control of bloating.

Frusenex 100 contains Furosemide 100mg, a high-dose loop diuretic used for rapid and effective management of severe fluid retention (edema) and refractory hypertension. Manufactured by Geno Pharmaceuticals, it is a potent generic alternative to Lasix 100mg, offering robust performance for patients with chronic heart failure, renal insufficiency, or hepatic edema. Its fluid-reducing effect also supports short-term dietary fluid management and bloating relief.

Diamox 250 is an oral medication containing Acetazolamide 250mg, a potent carbonic anhydrase inhibitor known for its diuretic, antihypertensive, antiepileptic, and anti-glaucoma properties. It acts by reducing the activity of carbonic anhydrase, an enzyme involved in fluid and ion balance, thereby lowering intraocular pressure, promoting urine output, and modulating central nervous system excitability. In the realm of lifestyle-related diseases, Diamox 250 serves as a supportive treatment for hypertension, helping reduce blood pressure by increasing urinary excretion of sodium and water. In dietary management, its swelling relief effects make it beneficial for reducing fluid retention and peripheral edema. This medication also plays a critical role in disease/symptom-based care, particularly for common eye disorders like glaucoma, where it helps reduce elevated intraocular pressure. Additionally, sleep & mental health applications include adjunctive treatment for epilepsy and, in some cases, indirect benefits for sleep improvement through intracranial pressure reduction.

Ozempic 1mg Prefilled Pen is the maximum approved weekly dose of semaglutide for the treatment of type 2 diabetes mellitus. It is a once-weekly injectable GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and delays gastric emptying. This triple mechanism helps lower both fasting and postprandial glucose levels. The 1mg dose is generally prescribed after titration through lower doses (0.25mg → 0.5mg) and is intended for patients who require enhanced glycemic control beyond the 0.5mg regimen. While semaglutide also reduces appetite and contributes to weight reduction, Ozempic is not approved by the FDA for obesity treatment. Any weight-related outcomes should be considered off-label and incidental.

Lonitab 5 is an oral tablet containing Minoxidil 5mg formulated to promote hair growth and manage androgenetic alopecia (male and female pattern baldness). Unlike topical solutions, this internal therapy improves scalp blood flow, supporting regrowth, thickness, and density. Originally developed as an antihypertensive vasodilator, Minoxidil showed robust hair-regrowth effects by increasing blood supply to follicles, reactivating dormant follicles and prolonging the anagen (growth) phase to help reduce ongoing hair loss. Oral Minoxidil can be considered for patients unresponsive to Topical Minoxidil or those seeking systemic therapy; monitoring is advised for fluid retention and blood-pressure changes.

Mounjaro 2.5mg is the initiation dose of tirzepatide, a groundbreaking dual incretin receptor agonist that targets both GLP‑1 and GIP pathways. Designed as a once-weekly subcutaneous injection, it is FDA-approved for the treatment of type 2 diabetes in adults and delivers robust glycemic control by enhancing insulin secretion, suppressing glucagon release, and delaying gastric emptying. The dual receptor targeting enables broader metabolic effects compared to GLP-1 monotherapy. Although significant weight reduction has been observed in clinical studies, Mounjaro is not approved for obesity treatment; its role in weight loss is considered secondary. Notably, emerging research suggests its potential to reduce the risk of progression from prediabetes, improve outcomes in patients with obesity-related obstructive sleep apnea (OSA), and possibly modulate long-term risks associated with metabolic diseases, including certain cancers. The 2.5mg dose is intended strictly for treatment initiation and is not meant for long-term maintenance.

Mounjaro 5mg is the first therapeutic dose of tirzepatide after the 2.5mg initiation period, representing the beginning of active glycemic management. As a once-weekly subcutaneous GLP-1/GIP dual receptor agonist, tirzepatide is approved for the treatment of type 2 diabetes in adults. Its innovative mechanism targets two complementary incretin pathways—GLP‑1 for appetite suppression and insulin secretion, and GIP for enhanced insulinotropic effects and fat metabolism. This dual action enables superior HbA1c reduction and metabolic rebalancing. Though not formally approved for weight loss, consistent reductions in body weight have been demonstrated, and tirzepatide plays a vital role in broader metabolic disease risk modulation. Early studies also indicate promise in slowing prediabetes progression, improving outcomes in obesity-linked obstructive sleep apnea, and possibly reducing the long-term risk of metabolic cancers. Mounjaro 5mg marks the start of personalized escalation, with further titration options based on patient response.

Lonitab 2.5 is an oral Minoxidil tablet designed to combat male and female pattern baldness (androgenic alopecia) by stimulating hair regrowth and preventing further hair loss. Manufactured by Intas Pharmaceuticals, it contains Minoxidil 2.5mg, a well-known vasodilator that enhances blood circulation to the scalp, reactivating dormant follicles and encouraging thicker, healthier hair growth. Unlike topical Minoxidil, which is applied to the scalp, Lonitab 2.5 provides systemic action, making it a convenient alternative for individuals seeking an oral hair restoration treatment.

Mounjaro 7.5mg is a once-weekly GLP-1 and GIP dual receptor agonist injection used to treat type 2 diabetes. Following the 2.5mg initiation phase and 5mg therapeutic baseline, the 7.5mg dose is a step-up in dosage escalation, offering enhanced glycemic control and additional metabolic benefits. While not primarily intended for weight loss or obesity treatment, many patients experience meaningful weight reduction as a secondary effect. This formulation is part of a broader titration strategy that supports gradual therapeutic intensification based on patient tolerability and HbA1c response.

Mounjaro 10mg is a once-weekly subcutaneous injection containing tirzepatide, a dual agonist that targets both GLP‑1 and GIP receptors. This dosage represents the third step in the titration sequence following 2.5mg, 5mg, and 7.5mg phases. It is designed for patients who have tolerated earlier doses and require enhanced glycemic control. Approved for the treatment of type 2 diabetes, this formulation supports both insulin secretion and delayed gastric emptying, contributing to improved HbA1c levels. Although weight loss is a well-documented secondary effect, this is not its primary approved indication—Zepbound is the weight-loss–specific formulation. The 10mg dose is widely recognized for balancing efficacy and tolerability, forming part of the individualized dose escalation path based on patient response.

Mounjaro 12.5mg is a once-weekly GLP‑1 and GIP dual agonist injection designed for glycemic control in type 2 diabetes. It is not primarily a weight loss drug but has shown consistent weight reduction across doses. This dose level represents an advanced therapeutic stage following titration from lower strengths (2.5mg, 5mg, 7.5mg, 10mg). While approved for diabetes, studies have explored off-label benefits in obesity-related conditions such as obstructive sleep apnea (OSA), prediabetes progression, and metabolic cancer modulation. Mounjaro’s dual incretin action supports enhanced insulin secretion and appetite regulation.

Arkamin 100 contains **Clonidine 100mg**, a centrally acting alpha-2 adrenergic agonist that exerts multiple therapeutic effects in both psychiatric and cardiovascular domains. Initially developed as an antihypertensive, Clonidine has evolved into a widely utilized agent in the management of **ADHD (especially pediatric cases accompanied by sleep disturbance)** and **neurocognitive regulation**. Its calming mechanism involves reducing sympathetic outflow from the brain, leading to decreased blood pressure and improved behavioral control. Clonidine is also studied for its impact on **executive function**, making it a supportive option in complex mental health treatment plans.

Mounjaro 15mg is the maximum titrated dose of tirzepatide, a dual agonist that targets both GLP‑1 and GIP receptors. This weekly injectable medication is FDA-approved for the treatment of type 2 diabetes mellitus and is known for significantly lowering HbA1c and fasting/postprandial glucose levels. While its primary indication is glycemic control, consistent metabolic weight loss has been observed across all dose levels, including 15mg, due to its appetite-suppressing and insulin-sensitizing actions. The compound is not approved for weight management under the Mounjaro label; however, its sister brand Zepbound is authorized for obesity treatment, reinforcing tirzepatide’s broad metabolic impact. Recent studies suggest additional off-label benefits including risk reduction in the progression from prediabetes to diabetes (up to 94% in some cohorts), supportive effects in obstructive sleep apnea (OSA) when comorbid with obesity, and potential cancer risk modulation in obesity-related cancers like breast cancer. Such extended benefits are under clinical investigation and should be referenced cautiously. Mounjaro 15mg serves as a dual-purpose agent — both for glycemic optimization and secondary metabolic improvements.

Arkamin 150 contains clonidine 150mg, a centrally acting alpha-2 adrenergic agonist that modulates sympathetic nervous system activity. Originally developed as an antihypertensive, clonidine is now widely used in psychiatric settings due to its calming effects on neural overactivity. It has proven especially useful for ADHD in children and adults, and is also employed in pain management and sleep-related disorders.

Lirafit 6mg is a GLP-1 receptor agonist developed by Glenmark, primarily used for the treatment of Type 2 diabetes and weight management. Containing Liraglutide 6mg, it mimics incretin hormones, enhancing insulin secretion, suppressing glucagon production, slowing gastric emptying, and reducing appetite. This once-daily injection aids in blood sugar regulation, metabolic health improvement, and cardiovascular risk reduction. It is suitable for adults and children over 10 years old.

Minoxyvy 2.5mg is an oral formulation of minoxidil, originally developed as an antihypertensive vasodilator but widely utilized off-label for hair restoration. Unlike topical applications, oral minoxidil delivers systemic absorption, promoting consistent results across the scalp including hairline and frontal regions. This makes it a preferred choice for individuals with diffuse thinning or those who have not responded adequately to topical solutions.

Minoxyvy 5mg is an oral minoxidil tablet primarily used off-label for treating androgenetic alopecia. Originally developed as a vasodilator for hypertension, minoxidil’s ability to enhance scalp blood flow and stimulate follicles has made it a popular choice for hair regrowth. The 5mg dosage is widely recognized as the most practical and effective strength for male-pattern baldness, offering a balance between efficacy and manageable side effects.